Gorgojo-Martinez, Juan J.; Basagoiti-Carreno, Belen; Sanz-Velasco, Alberto; Serrano-Moreno, Clara; Almodovar-Ruiz, Francisca published the artcile< Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study>, Category: amides-buliding-blocks, the main research area is obesity cardiovascular risk factor orlistat liraglutide.
To evaluate in a real-world setting the effectiveness of two drugs, orlistat and liraglutide, in patients with overweight or obesity and insufficient weight loss (WL) after a lifestyle modification program. Retrospective, observational cohort study comparing clin. outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI =30 kg/m2 or =27 kg/m2 with at least a weight-related comorbidity who had failed to lose at least 5% of their weight after 6 mo of lifestyle modification. The co-primary end-points, assessed at 3-6 mo and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs. Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included. WL with liraglutide (-7.7 kg) was significantly greater than that observed with orlistat (-3.3 kg), and more individuals lost at least 5% of their baseline weight with liraglutide (64.7%) than with orlistat (27.4%). In this real-world study, liraglutide showed a greater effectiveness in WL compared with orlistat and improved several obesity-associated metabolic and cardiovascular risk factors.
International Journal of Clinical Practice published new progress about Antiarrhythmics. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Category: amides-buliding-blocks.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics